Popular search terms:
Search Results
16 results found-
R&D Investor Briefing 2015
Commercial Opportunities Bob Repella . Q&A Break . Coagulation/Haemophilia . Clinical Medicines Specialty Products Haemophilia Products CSL Protein Therapeutics
https://www.cslbehring.com.au/-/media/shared/documents/7/rd-investor-briefing-2015.pdf -
Australia
With Alpha-1 deficiency CSL Behring Australia Haemophilia Foundation Australia Contribution in support of Haemophilia Foundation Australia (HFA) Patient Conference CSL
https://www.cslbehring.com.au/-/media/cslb-australia/documents/transparency-reports/csl-bhering-hcp-transparency-report-2015-pdf.pdf -
MonoFIX-VF
The information in this leaflet is subject to change. Please check with your haemophilia MonoFIX ® -VF is used in patients with haemophilia B or Christmas disease, a bleeding
https://www.cslbehring.com.au/-/media/cslb-australia/documents/aus-pis-and-cmis/monofixvf-au-cmi-2001.pdf -
Biostate
The information in this leaflet is subject to change. Please check with your Haemophilia Biostate ® is also used in patients with haemophilia A, a bleeding disorder, in which
https://www.cslbehring.com.au/-/media/cslb-australia/documents/aus-pis-and-cmis/biostate-au-cmi-v2400.pdf -
R&D Investor Briefing 2016
Commercial Opportunities Bob Repella . Q&A - Break - . Coagulation/Haemophilia . Clinical registered products Core Capabilities: Haemophilia Immunoglobulins Specialty Products
https://www.cslbehring.com.au/-/media/shared/documents/7/rd-investor-briefing-2016.pdf -
R&D Investor Briefing 2017
Early Development Charmaine Gittleson . Immunoglobulins, Haemophilia and Specialty Cycle Management # Immunoglobulins Haemophilia Specialty Products Influenza Vaccine
https://www.cslbehring.com.au/-/media/shared/documents/7/rd-investor-briefing-2017.pdf -
Our Company | CSL Behring Australia
CSL Behring is a global biotech company leading the way to deliver innovative therapies for rare and serious diseases.
https://www.cslbehring.com.au/our-company -
R&D Investor Briefing 2014
Commercial Opportunities Bob Repella . Q&A Break . Coagulation/Haemophilia . Clinical Medicines Specialty Products Haemophilia Products Immunoglobulins CSL R&D
https://www.cslbehring.com.au/-/media/shared/documents/7/rd-investor-briefing-2014.pdf -
Australian PI - Biostate (FVIII / VWF)
with FVIII deficiency due to haemophilia A. Biostate AU PI 26.00 Page 3 of 20 3 times a week should be considered. Haemophilia A population Provided in Table 3 are
https://www.cslbehring.com.au/-/media/cslb-australia/documents/aus-pis-and-cmis/biostate-au-pi-v2600.pdf -
Biostate Data Sheet
with FVIII deficiency due to haemophilia A. NEW ZEALAND DATA SHEET Biostate NZ NEW ZEALAND DATA SHEET Biostate NZ DS 18.00 Page 4 of 20 Haemophilia A population Provided
https://www.cslbehring.com.au/-/media/cslb-australia/documents/nz-dss/biostate-nz-ds1800.pdf